Pharma — India Patent Cases
967 decisions indexed
Page 30 of 33 · 967 total
Sun Pharmaceuticals Industries Ltd. v.Mukesh Kumar P. & Ors.
The Delhi High Court ruled in favor of Sun Pharmaceuticals Industries Ltd. (SPIL) against the defendants, finding that their use of the mark AMLOVATE constituted both trademark infringement and passing off against SPIL's registered mark, AMLOBET. The court affirmed SPIL's territorial jurisdiction despite the defendants' objections. Consequently, the suit was decreed with a permanent injunction and an order requiring the defendants to render accounts of profits.
F Hoffman La Rochee Ltd & Anr v.Cipla Ltd.
This appeal involved disputes between Roche and Cipla regarding Patent No. 196774, which covered a cancer treatment drug ('Polymer A'). While Cipla had raised counterclaims seeking revocation based on non-disclosure (Section 8), the Division Bench addressed whether to stay the IPAB proceedings pending the outcome of cross-appeals in the High Court.
Jagdale Industries Limited v.Halewood Laboratories Pvt. Ltd.
Jagdale Industries Limited appealed an order dismissing its application for leave to sue Halewood Laboratories Pvt. Ltd. and others regarding alleged infringement of Patent No. 247946, which covers a fruit juice based electrolyte energy drink. The High Court dismissed the appeal, holding that the appellant failed to demonstrate sufficient evidence or causal link showing that a part of the cause of action arose within the court's territorial jurisdiction.
Orchid Chemicals & Pharmaceuticals Ltd. v.Wockhardt Limited
Orchid Chemicals & Pharmaceuticals Ltd. appealed against the dismissal of its interim injunction application, alleging that Wockhardt Limited was infringing their registered trademark "METO" with "METOX". The court dismissed the appeal, holding that the appellant could not maintain the suit because the required assignment deed procedure under the Trade Marks Act, 1999, had not been completed.
Merck Sharp And Dohme Corporation v.Glenmark Pharmaceuticals Ltd
Merck Sharp And Dohme Corporation filed an application seeking an interim injunction against Glenmark Pharmaceuticals Ltd, alleging infringement of its patent on the molecule SITAGLIPTIN. The plaintiffs argued that the defendant's product infringed their patented composition and brand names (JANUVIA/JANUMET). However, the court dismissed the application, finding that the plaintiffs failed to plead necessary circumstances regarding prior unsuccessful applications for related patents.
Novartis Ag v.Union Of India & Ors
This landmark Supreme Court judgment addressed the critical interplay between Section 3(d) of the Patents Act, 1970, and the definition of 'invention.' The case centered on Novartis's claim for a patent covering the beta crystalline form of Imatinib Mesylate (marketed as Glivec/Gleevec), a life-saving drug. The Court was tasked with balancing the need to encourage pharmaceutical research and development against India’s commitment to ensuring affordable access to essential medicines, particularly in developing nations.
Vittal Mallya Scientific Research Foundation v.Indus Biotech Private Limited
Vittal Mallya Scientific Research filed a civil suit seeking permanent injunctions against Indus Biotech Private Limited for manufacturing and selling products (soluble double metal salt of HCA and anti obesity beverages) in violation of several process patents. The plaintiff subsequently moved to withdraw the suit as 'not pressed', which the court accepted, dismissing the case.
Sugen Inc. v.A. Rao & Anr.
The plaintiffs sued for injunction against infringement of Indian Patent No.209251, which covered the drug SUTENT. Although the Supreme Court initially set aside a revocation order, the Assistant Controller subsequently revoked the patent again. The court ultimately held that since the patent was revoked, the basis for the interim injunction disappeared, and the plaintiffs' application for continued relief was dismissed.
Cipla Ltd. v.Union Of India and Others
Cipla Ltd. challenged the grant of Patent No. 209251 by filing an application for revocation. The Controller subsequently revoked the patent based on the Opposition Board's recommendation. The Supreme Court set aside the Controller's order, finding that it violated the principle of natural justice because the parties were not provided with a copy of the Opposition Board's report.
Cipla Ltd. v.Union Of India And Ors.
Cipla Ltd. appealed an order passed by a Single Judge which restrained it from marketing its drugs. The original dispute involved the second respondent challenging the revocation of its patent by the Assistant Controller, arguing that provisions of Section 25(3) and (4) of the Patents Act were not followed. The High Court dismissed Cipla's appeal, upholding the interim restraint order.
F. Hoffmann-La Roche Ltd. v.Cipla Ltd.
F. Hoffmann-La Roche Ltd. (Roche) filed a suit against Cipla Ltd., alleging infringement of its patent for the cancer drug Erlotinib (marketed as Tarceva). The plaintiffs sought permanent injunctions and damages, asserting their exclusive rights under the Patent Act, 1970. However, after considering various issues, including whether the defendant's actions constituted infringement and whether the patent itself was valid, the court ultimately dismissed both the original suit and the counter-claim.
United Biotech Pvt. Ltd. v.Orchid Chemicals & Pharmaceuticals Ltd
The Delhi High Court dismissed the appeal filed by United Biotech Pvt. Ltd., upholding the Intellectual Property Appellate Board's decision to remove its trademark FORZID from the register. The court found that the respondent, Orchid Chemicals & Pharmaceuticals Ltd, had successfully demonstrated a likelihood of confusion between their earlier registered mark ORZID and the appellant's mark FORZID in the pharmaceutical sector. This judgment reinforces the principle that even sophisticated buyers can be misled by deceptively similar marks operating in the same field.
Astrazeneca Uk Ltd & Ors v.Orchid Chemicals & Pharmaceuticals Ltd.
The Delhi High Court dismissed an application filed by Orchid Chemicals seeking a stay of infringement proceedings against Astrazeneca. The court held that since Astrazeneca had previously challenged the validity of Orchid’s mark, Orchid was barred from filing rectification proceedings without first obtaining prima-facie satisfaction from the Court. The judgment emphasized judicial discipline and the principle of estoppel, preventing parties from taking contradictory pleas on the same issue.
Troikaa Pharmaceuticals Ltd v.Akums Drugs and Pharmaceuticals Ltd & 2
The suit concerned the dispute between Troikaa Pharmaceuticals Ltd and Akums Drugs regarding the manufacture of Diclofenac Sodicum Injection. The High Court modified an earlier ex-parte interim relief, based on a consensus reached by both parties in a previous appeal, extending the injunction until June 19, 2012.
Sun Pharmaceuticals Industries Limited v.Emcure Pharmaceuticals Limited
The Bombay High Court addressed a suit concerning trademark infringement and passing off between Sun Pharmaceuticals (owner of 'SUSTEN') and Emcure Pharmaceuticals (owner of 'SUSTINEX'). Although the plaintiff was the prior user, the court ultimately found that 'SUSTINEX' was not deceptively similar to 'SUSTEN'. The judgment emphasized phonetic distinctiveness, noting a clear audible divide in 'SUSTINEX', leading to the dismissal of the plaintiff's notice of motion.
Unknown v.S.K.Maingi
The plaintiffs filed a suit seeking permanent injunction and damages against the defendant for infringing Indian Patent No.196774, which covers Erlotinib Hydrochloride. The core legal issue before the Madras High Court was whether it had the necessary territorial jurisdiction to try the infringement case, given that the plaintiff was not a resident of Delhi and the alleged sales were isolated.
Natural Remedies Private Limited v.Indian Herbs Research & Supply Co Ltd
The plaintiff, Natural Remedies Pvt Ltd, filed a suit seeking permanent injunction against the defendants for manufacturing and selling 'Livoliv-250', alleging infringement of their protected Patent No. 186857 for 'A method of preparing a Herbal Hepatoprotective and Antihepatotoxic Composition' (Zigbir). The court found that the defendants did not follow the same patented process, and furthermore, the invention lacked an inventive step, leading to the patent being revoked.
Matrix Laboratories Limited v.F.Hoffman La Roche Ltd.
This appeal involved Matrix Laboratories Limited challenging an order that granted leave to sue regarding alleged infringement of Patent No. 196774, which covers Erlotinib Hydrochloride. The core dispute centered on whether the appellant's filing of a revocation petition before the IPA Board in Chennai created sufficient territorial jurisdiction for the Madras High Court to hear the suit. The court ultimately ruled that merely approaching the IPA Board does not automatically confer cause of action or jurisdiction, especially when the appellant's primary operations are elsewhere.
Respondents/Plaintiffs v.Applicant/Defendant
The plaintiffs filed a suit seeking permanent injunction against the defendant for infringing Indian Patent No.196774 related to the cancer drug EROLTINIB HYDROCHLORIDE (TARCEVA). The defendant subsequently filed an application to revoke the leave granted by the court, arguing lack of jurisdiction. The Court held that since the defendant approached the IPA Board in Chennai with a revocation petition, a part of the cause of action arose within its jurisdiction.
Pfizer Products Inc. v.B.P.Singh Tyagi
Pfizer successfully sued B.P.Singh Tyagi and his company for trademark infringement and passing off related to their cough syrup product. The Delhi High Court found that the defendant's mark, OREX, was phonetically and deceptively similar to Pfizer's registered mark, COREX. Consequently, the court granted a permanent injunction restraining the defendant from using the infringing mark and awarded punitive damages.
Pfizer Products Inc & Anr v.Vijay Shah & Ors.
Pfizer successfully sued a competitor for trademark infringement and passing off regarding its popular cough syrup, COREX. The Delhi High Court granted permanent injunctions restraining the defendants from using the deceptively similar mark SOREX and associated packaging/labels. Furthermore, the court awarded punitive damages to Pfizer, reinforcing the legal protection afforded to registered trademarks in the pharmaceutical sector.
Neon Laboratories Pvt.Ltd. v.Troikaa Pharma Limited
Neon Laboratories challenged the grant of Patent No.231479 held by Troikaa Pharma Limited, arguing that the company was prejudiced because it was not afforded an opportunity to oppose additional claims made during the examination process. The High Court set aside the patent grant and directed the Controller to conduct a fresh hearing on the original and amended claims.
M/S UCB FARCHIM SA v.M/S Cipla Ltd.
The petitions challenged orders passed by the Assistant Controller of Patents rejecting patent applications or related documents. The court examined the statutory scheme of the Patents Act, particularly concerning pre-grant and post-grant opposition procedures introduced by the 2005 Amendment Act.
Modi Mundi Pharma Pvt. Ltd. v.Matrix Formulations & Anr.
The Delhi High Court ruled in favor of Modi Mundi Pharma Pvt. Ltd., finding that the defendant's use of 'NEUROCONTIN-800' infringed upon the plaintiff's registered trademark 'CONTIN'. The court held that the resemblance between the marks was likely to cause confusion and deceive consumers, thereby amounting to passing off. Consequently, the suit was decreed, granting permanent injunctions against the defendants and ordering them to surrender all infringing materials.
Glochem Industries Ltd. v.Cadila Healthcare Ltd.
Glochem Industries Ltd. challenged an order passed by the Assistant Controller of Patents & Designs that dismissed its representation by way of opposition against Cadila Healthcare Ltd.'s patent application for Clopidogrel Besylate. The Petitioners argued that the invention lacked enhancement in therapeutic efficacy, which was a core ground for opposition under the Patents Act. The Bombay High Court set aside the dismissal order and directed the matter to be reconsidered afresh by the Patent Office.
Vittal Mallya Scientific Research Foundation v.Indfrag Limited
The applicants filed three applications seeking supplementary instructions to IIT, Madras, to examine whether the respondent's production process for Double Metal Salt of HCA infringed upon the applicants' patents. The court dismissed these applications, holding that they constituted an abuse of the process and were unnecessary since the trial was yet to commence.
Bayer Corporation v.Union of India
Bayer Corporation, holding a patent for the drug Sorafenib tosylate, challenged the licensing process of its competitor, Cipla, arguing that Cipla's application for 'Soranib' constituted an infringement. Bayer contended that granting the license would violate Section 48 of the Patents Act and contravene the definition of a 'spurious drug' under the Drugs and Cosmetics Act. The Delhi High Court ultimately dismissed the writ petition, holding that unpatented drugs cannot be deemed 'spurious drugs,' thereby upholding the procedural integrity of the licensing process.
The Petitioner/Appellant (Name not specified) v.Cadilla Pharmaceuticals Ltd
The Madras High Court dismissed a petition seeking an interim injunction against Cadilla Pharmaceuticals Ltd, which was accused of infringing the petitioner's registered trademark CEFI-XL with its mark CEFOLAC-XL. The court found that there was no prima facie case of deception or confusing similarity between the two marks. Furthermore, the court noted the petitioner's delay in bringing the action (laches) and concluded that the balance of convenience favored the respondent, thus denying the temporary injunction.
Aventis Pharmaceuticals Inc. and AMR Technology, Inc. v.Barr Laboratories, Inc., Ranbaxy Laboratories Ltd. and Ranbaxy Pharmaceuticals Inc.
Aventis Pharmaceuticals Inc. and AMR Technology, Inc. filed a petition seeking permission from the Punjab-Haryana High Court to execute a letter of request issued by the United States District Court for the District of New Jersey under the Hague Convention. The request sought evidence and documents related to patent infringement concerning Aventis's ALLEGRA® drug products manufactured using intermediates supplied by Ind-Swift Laboratories Ltd.
F. Hoffmann-La Roche Ltd. v.Cipla Ltd.
F. Hoffmann-La Roche Ltd. (Roche) appealed a decision that denied an interim injunction against Cipla Ltd. regarding the manufacturing and sale of the generic drug Erlocip, which is based on the patented molecule Erlotinib (Tarceva). The plaintiffs claimed patent rights over this cancer treatment. However, the Delhi High Court dismissed the appeal, finding that the defendant had raised credible challenges to both the validity of the patent and the prima facie case for infringement. Crucially, the court emphasized that public interest in greater access to life-saving drugs must outweigh the interest in granting an injunction.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.